Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Paediatric treatment regimens for acute lymphoblastic leukaemia in adolescents and young adults

Wendy Stock • 5 Dec 2014
ASH 2014
Acute Lymphoblastic Leukemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL) discusses the intergroup trial C10403, which showed that adolescent and young adult patients (16–39 years old) with acute lymphoblastic leukaemia had better overall and event-free survival with paediatric regimens compared to historical controls.

More from Wendy Stock

9:48
iwAL 2019: CAR-T & cellular therapies in AML and ALL
Bianca Santomasso et al. • 28 May 2019
4:44
Emerging novel approaches for ALL: inotuzumab ozogamicin
Wendy Stock • 4 May 2018
2:39
Support systems are a crucial factor in ALL treatment
Wendy Stock • 4 May 2018
2:22
Next-generation methodologies: the future for MRD monitoring in ALL?
Wendy Stock • 4 May 2018

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals